New Issue: Orbital Catastrophe Ahead? Read Now

Nanoparticles Pass Muster as Vectors for Gene Therapy

Join Our Community of Science Lovers!


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Gene therapy, in which a viral vector is used to modify defective genes or replace missing ones, has shown significant potential as a way of treating disease in animal models. But its use in humans has been hampered by safety concerns, including some fatalities in clinical trials. Researchers have thus been looking into the possibility of using nonviral vectors, which should carry fewer inherent risks, to deliver therapeutic genes. In a paper published online this week by the Proceedings of the National Academy of Sciences, scientists report that silicon nanoparticles can perform this task successfully in mice.

Paras N. Prasad of the State University of New York (SUNY) at Buffalo and his colleagues manufactured nanoparticles using organically modified silicon. The surface of these particles can be tailored to target specific cells. The team used the tiny units to transport a fluorescent marker gene to dopamine neurons in the brains of mice. After injecting the nanoparticles, the researchers observed brain cells fluorescing using a new imaging technique that works on live animals. According to the report, the study is the first in which a nonviral vector has shown efficacy comparable to that of a viral delivery system in an animal model. What is more, a month later none of the animals had experienced adverse effects from the procedure.

The researchers also investigated the possibility of manipulating the behavior of specific brain cells, instead of solely tagging their presence. In so doing, they discovered that the nanoparticles can be used to reactivate adult stem cells by altering a nuclear growth factor receptor. The team will next test the approach on larger animals. "In the future," says study co-author Earl J. Bergey, also at SUNY Buffalo, "this technology may make it possible to repair neurological damage caused by disease, trauma or stroke."

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe